Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1955 2
1958 1
1959 1
1964 2
1965 7
1966 12
1967 20
1968 28
1969 14
1970 18
1971 18
1972 20
1973 24
1974 20
1975 24
1976 14
1977 35
1978 20
1979 26
1980 23
1981 35
1982 45
1983 45
1984 46
1985 60
1986 45
1987 49
1988 59
1989 50
1990 47
1991 41
1992 53
1993 39
1994 14
1995 10
1996 8
1997 5
1998 14
1999 4
2000 12
2001 3
2002 5
2003 3
2004 8
2005 5
2006 7
2007 8
2008 4
2009 6
2010 5
2011 9
2012 1
2013 9
2014 6
2015 4
2016 1
2017 4
2018 5
2019 5
2020 2
2022 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,109 results

Results by year

Filters applied: . Clear all
Page 1
Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy.
Wood GE, Bunting CP, Veli M, Arora R, Berney DM, Alifrangis C, MacDonald ND, Miller RE, Shamash J, Stoneham S, Lockley M. Wood GE, et al. Front Oncol. 2023 Oct 25;13:1271647. doi: 10.3389/fonc.2023.1271647. eCollection 2023. Front Oncol. 2023. PMID: 37954076 Free PMC article.
Here, we comprehensively review the biological features of dysgerminoma and seminoma to demonstrate that they are biologically analogous diseases. We present available clinical trial data supporting de-escalation of chemotherapy treatment. ...
Here, we comprehensively review the biological features of dysgerminoma and seminoma to demonstrate that they are biologically analog …
Study of neoadjuvant chemotherapy in advanced malignant ovarian germ cell tumors at a tertiary center in western India.
Vasanth A, Patel SM, Arora R, Parekh CD, Dave P, Patel BM, Vemanamandhi P. Vasanth A, et al. J Gynecol Oncol. 2024 Mar;35(2):e19. doi: 10.3802/jgo.2024.35.e19. Epub 2023 Oct 23. J Gynecol Oncol. 2024. PMID: 37921603 Free PMC article.
OBJECTIVE: To study clinical characters and outcomes in patients of malignant ovarian germ cell tumor (MOGCT) undergoing surgery following neoadjuvant chemotherapy (NACT). ...Patient's median age was 22 years (range, 12 to 35 years) and median follow up 42months (range, 6 …
OBJECTIVE: To study clinical characters and outcomes in patients of malignant ovarian germ cell tumor (MOGCT) undergoing surgery foll …
Primary ovarian tumors in children: a single center experience of 124 patients.
Cemaloğlu M, Kutluk T, Varan A, Orhan D, Tanyel C, Aydın B, Kurucu N, Yalçın B, Akyüz C. Cemaloğlu M, et al. Turk J Pediatr. 2023;65(2):245-256. doi: 10.24953/turkjped.2022.659. Turk J Pediatr. 2023. PMID: 37114690 Free article.
We reviewed our 40-year experience with ovarian tumors to evalute the clinical features and treatment results in a single institution. METHODS: Between January 1975 and October 2015, 124 girls with primary ovarian tumor were diagnosed and treated in our center. ...Amongst …
We reviewed our 40-year experience with ovarian tumors to evalute the clinical features and treatment results in a single institution …
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, Roche KL, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, Chi DS, Aghajanian C, Feldman DR. Liu YL, et al. Gynecol Oncol. 2023 Mar;170:93-101. doi: 10.1016/j.ygyno.2022.12.022. Epub 2023 Jan 18. Gynecol Oncol. 2023. PMID: 36669327 Free PMC article.
In dysgerminomas, good- and intermediate-risk groups are defined by absence/presence of non-pulmonary/peritoneal visceral metastasis. ...Even within stage groups, mIGCCCG risk classifications were associated with clinical outcomes. CONCLUSIONS: A female-specific mIG …
In dysgerminomas, good- and intermediate-risk groups are defined by absence/presence of non-pulmonary/peritoneal visceral metastasis. …
Diagnosis and Management of Dysgerminomas with a Brief Summary of Primitive Germ Cell Tumors.
Mitranovici MI, Chiorean DM, Mureșan MC, Buicu CF, Moraru R, Moraru L, Cotoi TC, Cotoi OS, Toru HS, Apostol A, Turdean SG, Mărginean C, Petre I, Oală IE, Simon-Szabo Z, Ivan V, Pușcașiu L. Mitranovici MI, et al. Diagnostics (Basel). 2022 Dec 9;12(12):3105. doi: 10.3390/diagnostics12123105. Diagnostics (Basel). 2022. PMID: 36553112 Free PMC article. Review.
Dysgerminoma represents a rare malignant tumor composed of germ cells, originally from the embryonic gonads. Regarding its incidence, we do not have precise data due to its rarity. Dysgerminoma occurs at a fertile age. The preferred treatment is the surgical removal
Dysgerminoma represents a rare malignant tumor composed of germ cells, originally from the embryonic gonads. Regarding its incidence,
[Management of intra-abdominal dysgerminoma During pregnancy - A Case Report and Literature Review].
Litzka C, Leebmann H, Wiesinger H, Kirchner T, Seelbach-Göbel B, Häusler SFM. Litzka C, et al. Z Geburtshilfe Neonatol. 2020 Oct;224(5):306-314. doi: 10.1055/a-1112-0506. Epub 2020 Apr 2. Z Geburtshilfe Neonatol. 2020. PMID: 32242331 Review. German.
INTRODUCTION: Dysgerminomas are rare malignant germ cell tumors. They usually arise from the ovary, but case reports describing extraovarian dysgerminomas do exist. When treated adequately the disease has a good prognosis. Dysgerminomas diagnosed during pregn …
INTRODUCTION: Dysgerminomas are rare malignant germ cell tumors. They usually arise from the ovary, but case reports describing extra …
Variation of Gonadal Dysgenesis and Tumor Risk in Patients With 45,X/46,XY Mosaicism.
Matsumoto F, Matsuyama S, Matsui F, Yazawa K, Matsuoka K. Matsumoto F, et al. Urology. 2020 Mar;137:157-160. doi: 10.1016/j.urology.2019.12.014. Epub 2019 Dec 27. Urology. 2020. PMID: 31883875
Pathologic examination revealed gonadal tumors in 6 of the 34 (18%) patients, including a gonadoblastoma in 7 gonads among 5 patients and an association of dysgerminoma with gonadoblastoma in 1 gonad. All 6 patients who developed gonadal tumor had female genitalia. ...
Pathologic examination revealed gonadal tumors in 6 of the 34 (18%) patients, including a gonadoblastoma in 7 gonads among 5 patients and an …
Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution.
Hu T, Fang Y, Sun Q, Zhao H, Ma D, Zhu T, Wang C. Hu T, et al. Surg Oncol. 2019 Dec;31:8-13. doi: 10.1016/j.suronc.2019.08.006. Epub 2019 Aug 20. Surg Oncol. 2019. PMID: 31446304
Multivariate survival analysis was performed using Cox's proportional hazards model. RESULTS: There were 29 dysgerminomas (DG), 3 embryonal carcinomas (EC), 43 immature teratomas (IT), 48 yolk sac tumors (YST) and 14 mixed germ cell tumors (mGCT). ...It might be safe to pr …
Multivariate survival analysis was performed using Cox's proportional hazards model. RESULTS: There were 29 dysgerminomas (DG), 3 emb …
Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN).
Chan Wah Hak C, Coyle C, Kocache A, Short D, Sarwar N, Seckl MJ, Gonzalez MA. Chan Wah Hak C, et al. BMC Cancer. 2019 Aug 5;19(1):770. doi: 10.1186/s12885-019-5968-7. BMC Cancer. 2019. PMID: 31382912 Free PMC article.
BACKGROUND: Etoposide (E) at 100 mg/m(2) combined with Cisplatin (P) at 20 mg/m(2) represents an induction 2-day regimen embedded in our clinical practice for patients with advanced GCT or TN at high risk of early death. ...Half the cases were GCT (n = 52): 22 male (6 semi …
BACKGROUND: Etoposide (E) at 100 mg/m(2) combined with Cisplatin (P) at 20 mg/m(2) represents an induction 2-day regimen embedded in our …
Outcome of Metastatic and Recurrent Ovarian Dysgerminoma Using Radiation Therapy and Chemotherapy in a Dog.
Wilcox CL, Hansen KS, Kent MS, Phillips KL, Willcox JL. Wilcox CL, et al. J Am Anim Hosp Assoc. 2019 Jul/Aug;55(4):e55402. doi: 10.5326/JAAHA-MS-6893. Epub 2019 May 17. J Am Anim Hosp Assoc. 2019. PMID: 31099610
An 8 yr old female spayed poodle/terrier mixed-breed dog was referred for evaluation of a recurrent and metastatic ovarian dysgerminoma. A total dose of 20Gy was administered to both the mediastinal metastatic lesion and retroperitoneal recurrent dysgerminoma in fiv …
An 8 yr old female spayed poodle/terrier mixed-breed dog was referred for evaluation of a recurrent and metastatic ovarian dysgerminoma
1,109 results